Methylphenidate in the treatment of coma.
While there is significant morbidity and mortality involving patients in semicomatose and comatose states, the care of such patients has traditionally been limited to supportive measures. We report two cases of patients treated with methylphenidate hydrochloride: the first, a patient in a semicomatose state resulting from traumatic brain injury, and the second, a patient in a comatose state secondary to a subdural hematoma that occurred after a fall. Treatment with methylphenidate may provide neurostimulations by augmenting the activity of injured neuronal tissue within the reticular activating system, and by amplifying the net effect of the reduced number of viable neurons. Methylphenidate is a low-cost, potentially efficacious intervention for reducing the duration of comas, for preventing life-threatening and costly complications of prolonged unconsciousness, and for promoting early ambulation and recovery. Further research using more rigorous research designs to ascertain the effectiveness of methylphenidate in the treatment of patients in semicomatose and comatose states is needed.
Worzniak
M
M
Family Practice Residency Program, Oakwood Hospital and Medical Center, Dearborn, MI 48123-2500, USA.
Fetters
M D
MD
Comfort
M
M
D000058:Accidental Falls; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001930:Brain Injuries / Q000150:complications; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D003128:Coma / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D015600:Glasgow Coma Scale; D006408:Hematoma, Subdural / Q000209:etiology; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*
D000697:Central Nervous System Stimulants; D008774:Methylphenidate